-- Reaching agreement on risk factors, often one of the most challenging internal conversations for drug developers, is key to estimating overall clinical development costs and requires a multi-disciplinary team assessment. -- Reducing complexity is important, and means identifying from the beginning who in each company is responsible for which elements of the transaction. -- Developing an in-licensing culture requires continuous re-assessment and recalibration of terms, roles, and support systems. Knowing what worked well previously, backed up by good data, is important, but not necessarily gospel.Scheduled Tufts CSDD Executive Forum Roundtables Upcoming Tufts CSDD Executive Forum Roundtable meetings in 2009 will focus on the following:
* May 14 - Outsourcing: Economic and Operational Assessments * Sept. 10 - Best R&D Practices of Top Pharma/Biotech Performers * Nov. 12 - Comparative Approaches to Capacity ForecastingTo learn more, call 617-636-2170. About the Tufts Center for the Study of Drug Development The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes the Tufts CSDD Impact Report, a bi-monthly newsletter providing analysis and insight into critical drug development issues.
Contact Information: Contact: Tufts Center for the Study of Drug Development Charlene Neu 617-636-2187 Business Communication Strategies Peter Lowy 617-734-9980